Patent issues in drug development: Perspectives of a pharmaceutical scientist-attorney
Journal Title: The AAPS Journal - Year 2005, Vol 7, Issue 3
Abstract
The major purpose of this article is to emphasize the need for pharmaceutical scientists to have a better understanding of patent fundamentals. This need is illustrated by analyses of key scientific and legal issues that arose during recent patent infringement cases involving Prozac, Prilosec, and Buspar. Economic incentives for drug discovery and development clash with societal needs for low-cost pharmaceuticals in the United States and all over the world. The Hatch-Waxman Act of 1984 was enacted to promote public health by balancing the interests of brand name and generic companies. Patent protection, which provides a monopoly for a limited time, is aimed to provide such incentives. Creation of patents requires the interaction between scientists and lawyers, an endeavor made difficult by the differing intellectual spheres of their respective disciplines. Therefore, in the first place, a thorough understanding of patent fundamentals among pharmaceutical scientists will help them work more efficiently with patent attorneys. Second, it will enable them to appreciate the strengths and weaknesses of individual patents, which is critical in developing strategies amidst the ongoing patent tug-of-war between brandname and generic companies.
Authors and Affiliations
Srikumaran Melethil
Keywords
Related Articles
- EP ID EP681911
- DOI 10.1208/aapsj070372
- Views 92
- Downloads 0
A Rational, Systematic Approach for the Development of Vaccine Formulations
With the continuous emergence of new infectious diseases and new strains of current diseases, such as the novel H1N1 influenza in 2009, in combination with expanding competition in the vaccine marketplace, the pressure t...
Hemoglobin-derived Peptides as Novel Type of Bioactive Signaling Molecules
Most bioactive peptides are generated by proteolytic cleavage of large precursor proteins followed by storage in secretory vesicles from where they are released upon cell stimulation. Examples of such bioactive peptides...
Determination of carryover and contamination for mass spectrometry-based chromatographic assays
The Third American Association of Pharmaceutical Scientists/Food and Drug Administration Bioanalytical Workshop, held in 2006, reviewed and evaluated current practices and proposed that carryover and contamination be ass...
Introduction to the Proposals from the Global Bioanalysis Consortium Harmonization Team
At the initiative of four regional professional organizations from Europe (European Bioanalysis Forum (EBF)) and North America (AAPS, Applied Pharmaceutical Analysis (APA) APA and Calibration & validation group (...
Nanoparticles in Vaccine Delivery